SGLT2 Inhibition Updates 2021 - SGLT2 Inhibition in Cardiorenal Disease
Published: 20 July 2021
9m 18sPart 1 | Session 3 SGLT2 Inhibitors: Evolution from Glucose Lowering to Cardiorenal Protection
12m 18sPart 1 | Session 4 SGLT2 Inhibitors in Cardiology Indications: The Data
9m 38sPart 1 | Session 5 SGLT2 Inhibitors in Chronic Kidney Disease: The Data
14m 38sPart 1 | Session 6 Panel Discussion
9m 39sPart 2 | Session 1 Place of SGLT2 Inhibitors in the Heart Failure Treatment Algorithm
8m 1sPart 2 | Session 2 SGLT2 Inhibitors: Safety Considerations
7m 39sPart 2 | Session 3 How to Use SGLT2 Inhibitors in Daily Practice
6m 58sPart 2 | Session 4 Panel Discussion
1m 20sPart 6 | Session 1 Welcome and Introduction
11m 2sPart 6 | Session 2 How do SGLT2 Inhibitors Bring About Cardiorenal Benefits?
11m 24sPart 6 | Session 3 Totality of Evidence in Heart Failure
11m 20sPart 6 | Session 4 Trial Results Coming Out Soon
10m 55sPart 6 | Session 5 Heart Failure Guidelines
14m 37sPart 6 | Session 6 Panel Discussion
Organised with scientific co-chairs Stefan Anker and Andrew Coats, this event includes presentations and panel discussions with a host of international thought-leaders.
The SGLT2 Updates 2021 conference SGLT2 Inhibition in Cardiorenal Disease: Translating Evidence into Clinical Practice covers the place of SGLT2 inhibitors in the newly released guidelines of the Heart Failure Association (HFA) of the European Society of Cardiology (ESC) as well as their implementation in clinical practice.
In addition to plenary sessions and satellite symposia the conference featured a number of Meet The Expert breakout sessions discussing the implications in treatment of specific patient subgroups including patients with comorbidities. Audience questions were submitted throughout and were addressed by the panel experts.
SGLT2 Inhibition in Cardiorenal Disease
- Prepare cardiologists, nephrologists and endocrinologists to effectively manage patients with heart failure, individually and collaboratively
- Apply findings from clinical trials into clinical practice
- Describe the role of SGLT2 inhibitors in different patient subgroups, including patients with comorbidities
- Evaluate the safety and cardiorenal benefits of glucose-lowering agents
- Implement the new guidelines of the HFA of the ESC in clinical practice
More from this programme
State of the Art 1
SGLT2 Inhibitors in Heart Failure: A Practical Approach
Meet The Expert: Implications for Clinical Practice - Breakout 1
Meet The Expert: Implications for Clinical Practice - Breakout 2
Meet The Expert: Implications for Clinical Practice - Breakout 3
State of the Art 2
SGLT2 Inhibitors for Heart Failure: The New Standard of Care
Meet The Expert: Implications for Clinical Practice - Breakout 4
Meet The Expert: Implications for Clinical Practice - Breakout 5
Meet The Expert: Implications for Clinical Practice - Breakout 6
Professor of Cardiology
Prof Stefan Anker is professor of (Tissue) Homeostasis in Cardiology & Metabolism at Charité Berlin, Germany, since June 2017. Prodigious researcher who has authored more than 1,000 articles. He has also won several prizes, including the 2018 Copernicus Prize of German DFG & Polish FNP. In October 2020, he was awarded a Doctor honoris causa of Medical University Wroclaw, Poland.
Prof Anker has been serving on the board of the Heart Failure Association (HFA) of the ESC since 2006 and was HFA President from 2012 to 2014. He currently chairs the HFA committee on regulatory affairs. He is founding Editor-in-Chief of the first open-access heart failure journal, ESC Heart Failure. Prof. Anker has served on several ESC Guideline task forces.
Prof Anker is the founding president of the International Society on Sarcopenia, Cachexia and Wasting Disorders (SCWD) and founding Editor-in-Chief of the Journal of Cachexia, Sarcopenia and…
Director, Heart Failure and Heart Transplant Clinics
Dr Shelley Zieroth is Professor at the College of Medicine, Max Rady Faculty of Health Sciences, University of Manitoba, as well as Director of the Heart Failure and Heart Transplant Clinics at St Boniface Hospital in Winnipeg, Canada. She is also Head of the Medical Heart Failure Program for Cardiac Sciences Manitoba.
She is involved in several heart failure clinical trials as a PI, National Lead or Executive Committee member. She is the Past President of the Canadian Heart Failure Society and Co-Chair of the Canadian Cardiovascular Society Heart Failure Guidelines. She is co-chair of Canada’s largest annual heart failure meeting, HF Update, and Past President of the Federation of Medical Women of Canada.
Dr Shelley Zieroth is an Editorial Board member of Cardiac Failure Review.